Cargando…

Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure

AIMS: The angiotensin receptor–neprilysin inhibitor (ARNI), sacubitril/valsartan, confers additional protective effects compared with angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers (ACEIs/ARBs) in terms of reversed left ventricular (LV) remodelling and improves the prognos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Yuxi, Song, Shuang, Zhang, Yanli, Mo, Wenqiong, Zhang, Xinxin, Wang, Ning, Xia, Yunlong, Tse, Gary, Liu, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787963/ https://www.ncbi.nlm.nih.gov/pubmed/34779134 http://dx.doi.org/10.1002/ehf2.13691

Ejemplares similares

Reverse Atrial Remodeling in Heart Failure With Recovered Ejection Fraction
por: Sun, Yuxi, et al.
Publicado: (2023)

Effects of rhythm control on left atrial structure remodeling in atrial fibrillation and heart failure with preserved ejection fraction
por: Bai, Lin, et al.
Publicado: (2023)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
por: Ryazanov, A.S., et al.
Publicado: (2023)

Effect of angiotensin receptor-neprilysin inhibitor on atrial electrical instability in atrial fibrillation
por: Zhu, Tianyu, et al.
Publicado: (2022)

Characterization of heart failure patients with reverse left ventricular remodelling post‐angiotensin receptor blockers/neprilysin inhibitors therapy
por: Maizels, Leonid, et al.
Publicado: (2022)

Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure
por: Pfau, Daniel, et al.
Publicado: (2019)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Characteristics and outcomes of heart failure with recovered left ventricular ejection fraction
por: Zhang, Xinxin, et al.
Publicado: (2021)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
por: Dizaye, Kawa, et al.
Publicado: (2019)

Effects of the Angiotensin‐Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta‐Analysis
por: Wang, Yiwen, et al.
Publicado: (2019)

Angiotensin Receptor‐Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension
por: Sharifi Kia, Danial, et al.
Publicado: (2020)

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
por: Singh, Jagdeep SS, et al.
Publicado: (2015)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
por: Verbrugge, Frederik H., et al.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation
por: Dong, Youzheng, et al.
Publicado: (2023)

Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40%
por: Zhao, Mingyue, et al.
Publicado: (2019)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
por: Cho, In-Jeong, et al.
Publicado: (2021)

Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure
por: Kashiwagi, Yusuke, et al.
Publicado: (2023)

Efficacy of guideline‐directed medical treatment in heart failure with mildly reduced ejection fraction
por: Zhang, Xinxin, et al.
Publicado: (2022)

Immunomodulatory Treatment Strategies Targeting B Cells for Heart Failure
por: Zhang, Xinxin, et al.
Publicado: (2022)

Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40%: Retraction
Publicado: (2019)

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
por: Choi, Hong-Mi, et al.
Publicado: (2020)

The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials
por: Chen, Yan, et al.
Publicado: (2022)

Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism
por: Kashiwagi, Yusuke, et al.
Publicado: (2022)

Predictive Value of HFA-PEFF Score in Patients With Heart Failure With Preserved Ejection Fraction
por: Sun, Yuxi, et al.
Publicado: (2021)

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696
por: Li, Bo, et al.
Publicado: (2017)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
por: Sutanto, Henry, et al.
Publicado: (2021)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
por: Esser, Nathalie, et al.
Publicado: (2022)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series
por: Taghavi, Sepideh, et al.
Publicado: (2020)

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
por: Tsai, Ming-Lung, et al.
Publicado: (2023)

Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling
por: Docherty, Kieran F., et al.
Publicado: (2020)

The Application of Angiotensin Receptor Neprilysin Inhibitor in Cardiovascular Diseases: A Bibliometric Review From 2000 to 2022
por: Xu, Xia, et al.
Publicado: (2022)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Narrative review in the current role of angiotensin receptor-neprilysin inhibitors
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021)

Acute Tubular Necrosis Associated with Angiotensin Receptor-neprilysin Inhibitor
por: Kim, Moo Jun, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
por: Li, Kangbo, et al.
Publicado: (2023)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Is there a place for angiotensin receptor-neprilysin inhibitors in the treatment of heart failure patients after heart transplantation?
por: Gulin, Dario, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n4vh3hk2lk2j1cchtuubmfdtnj